These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38216715)

  • 1. Disease activity trajectories in juvenile dermatomyositis from childhood to adulthood.
    Nozawa T; Pullenayegum EM; Bell-Peter A; Marcuz JA; Whitney K; Vinik O; Shupak R; Dover S; Feldman BM
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI129-SI135. PubMed ID: 38216715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and prediction of novel classes of long-term disease trajectories for patients with juvenile dermatomyositis using growth mixture models.
    Deakin CT; Papadopoulou C; McCann LJ; Martin N; Al-Obaidi M; Compeyrot-Lacassagne S; Pilkington CA; Tansley SL; McHugh NJ; Wedderburn LR; De Stavola BL;
    Rheumatology (Oxford); 2021 Apr; 60(4):1891-1901. PubMed ID: 33146389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis.
    Gitiaux C; De Antonio M; Aouizerate J; Gherardi RK; Guilbert T; Barnerias C; Bodemer C; Brochard-Payet K; Quartier P; Musset L; Chazaud B; Desguerre I; Bader-Meunier B
    Rheumatology (Oxford); 2016 Mar; 55(3):470-9. PubMed ID: 26424834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus.
    Lim LSH; Pullenayegum E; Feldman BM; Lim L; Gladman DD; Silverman ED
    Arthritis Care Res (Hoboken); 2018 May; 70(5):750-757. PubMed ID: 28704581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Sanner H; Sjaastad I; Flatø B
    Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pulmonary function and autoantibodies in a long-term follow-up of juvenile dermatomyositis patients.
    Mathiesen PR; Buchvald F; Nielsen KG; Herlin T; Friis T; Nielsen S
    Rheumatology (Oxford); 2014 Apr; 53(4):644-9. PubMed ID: 24310298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis.
    Schmeling H; Stephens S; Goia C; Manlhiot C; Schneider R; Luthra S; Stringer E; Feldman BM
    Rheumatology (Oxford); 2011 May; 50(5):885-93. PubMed ID: 21156669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies.
    Martin N; Krol P; Smith S; Murray K; Pilkington CA; Davidson JE; Wedderburn LR;
    Rheumatology (Oxford); 2011 Jan; 50(1):137-45. PubMed ID: 20823094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index.
    Rider LG; Lachenbruch PA; Monroe JB; Ravelli A; Cabalar I; Feldman BM; Villalba ML; Myones BL; Pachman LM; Rennebohm RM; Reed AM; Miller FW;
    Arthritis Rheum; 2009 Nov; 60(11):3425-35. PubMed ID: 19877055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset.
    Sanner H; Gran JT; Sjaastad I; Flatø B
    Rheumatology (Oxford); 2009 Dec; 48(12):1541-7. PubMed ID: 19776224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical features of juvenile dermatomyositis: A single-centre inception cohort.
    Cancarini P; Nozawa T; Whitney K; Bell-Peter A; Marcuz JA; Taddio A; Guo J; Dover S; Feldman BM
    Semin Arthritis Rheum; 2022 Dec; 57():152104. PubMed ID: 36183479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.
    Challa D; Crowson CS; Niewold TB; Reed AM;
    Clin Rheumatol; 2018 Apr; 37(4):1011-1015. PubMed ID: 29170979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muscle MRI at the time of questionable disease flares in Juvenile Dermatomyositis (JDM).
    Abdul-Aziz R; Yu CY; Adler B; Bout-Tabaku S; Lintner KE; Moore-Clingenpeel M; Spencer CH
    Pediatr Rheumatol Online J; 2017 Apr; 15(1):25. PubMed ID: 28403889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.
    Rider LG; Shah M; Mamyrova G; Huber AM; Rice MM; Targoff IN; Miller FW;
    Medicine (Baltimore); 2013 Jul; 92(4):223-243. PubMed ID: 23877355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective.
    Boros C; McCann L; Simou S; Cancemi D; Ambrose N; Pilkington CA; Cortina-Borja M; Wedderburn LR;
    Pediatr Rheumatol Online J; 2022 Nov; 20(1):102. PubMed ID: 36384526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of myxovirus-resistance protein A: a possible marker of muscle disease activity and autoantibody specificities in juvenile dermatomyositis.
    Soponkanaporn S; Deakin CT; Schutz PW; Marshall LR; Yasin SA; Johnson CM; Sag E; Tansley SL; McHugh NJ; Wedderburn LR; Jacques TS
    Neuropathol Appl Neurobiol; 2019 Jun; 45(4):410-420. PubMed ID: 29770465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The lung is involved in juvenile dermatomyositis.
    Pouessel G; Deschildre A; Le Bourgeois M; Cuisset JM; Catteau B; Karila C; Nève V; Thumerelle C; Quartier P; Tillie-Leblond I
    Pediatr Pulmonol; 2013 Oct; 48(10):1016-25. PubMed ID: 23281200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus.
    Lim LSH; Pullenayegum E; Lim L; Gladman D; Feldman B; Silverman E
    Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1627-1635. PubMed ID: 28118527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of cardiorespiratory fitness in patients with juvenile dermatomyositis.
    Blom KJ; Takken T; Huijgen BCH; Wienke J; van Royen-Kerkhof A; van Brussel M
    Rheumatology (Oxford); 2017 Dec; 56(12):2204-2211. PubMed ID: 29029283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcome in children with juvenile dermatomyositis: A single-center study from north India.
    Sharma A; Gupta A; Rawat A; Suri D; Singh S
    Int J Rheum Dis; 2020 Mar; 23(3):392-396. PubMed ID: 31793219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.